clinical trial · NCT05226780
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
SCN8A Developmental and Epileptic Encephalopathy SyndromeNBI-921352
brief summary
Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).
started
Jul 12, 2022
primary completion
Nov 12, 2025
completion
Nov 12, 2025
last updated
Nov 13, 2026
official title
A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol